A Case of Cerebral Venous Sinus Thrombosis Following Eltrombopag in Immune Thrombocytopenia.

Eltrombopag is a second-line treatment option for patients with immune thrombocytopenic purpura (ITP) who have persistent thrombocytopenia. Although generally considered safe, it has been associated with uncommon thromboembolic complications. We report an 18-year-old female with ITP who developed superior sagittal sinus thrombosis after starting eltrombopag. Eltrombopag was discontinued, and anticoagulation was initiated with subsequent clinical improvement. This case highlights a serious complication of eltrombopag therapy and underscores the need for vigilant monitoring of platelet counts, timely dose adjustment, and early recognition of thrombotic events in patients with ITP receiving thrombopoietin receptor agonists.